[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases. 37 patients suffering from GERD underwent monotherapy with inhibitors of the proton pump: 17 patients were taking Omeprazole 40 mg a day, and 20 patients--Rabeprazole 20 mg a day. The treatment with Rabeprazole supplied authentic data concerning faster pain reduction in the heart area and heartburn starting from the first day of treatment. According to the daily pH monitoring, administration of Pariet is accompanied by a reliably much more manifested reduction of the total time with pH less than 4 in the esophagus as compared to Omeprazole. The data received demonstrate the advantages of using Pariet in the treatment of GERD with atypical symptoms.
Maev
I V
IV
Moscow State Medical and Dental Institute.
Kucheriavyĭ
Iu A
IuA
Danilin
M S
MS
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D002637:Chest Pain / Q000150:complications* / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D017494:Proton Pumps / Q000627:therapeutic use*; D064750:Rabeprazole; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D017494:Proton Pumps; D064750:Rabeprazole; D009853:Omeprazole